Why carry out this study?

Data on the real-world effectiveness and tolerance of baricitinib for treatment of alopecia areata are limited.

This retrospective observational study assessed the effectiveness and tolerance of baricitinib for the treatment of alopecia areata in a tertiary university hospital.

What was learned from this study?

This real-life study assessed the effectiveness and tolerance of baricitinib in alopecia areata in a series of 19 adults with a median follow-up of 13 months.

Results were better than in clinical trials; patients with patchy alopecia areata had a better hair regrowth prognosis than those with universalis.

Safety profile was reassuring; induced lipid changes were the most frequent adverse events.